Novartis Competitive Intelligence & Landscape

Novartis aims to become the most valued and trusted medicines company globally, delivering sustainable performance for its patients, employees, shareholders, and society [novartis.com/about], [novartis.com/investors]. The company's medicines reach hundreds of millions of people worldwide; in 2025, it reached more than 304 million people globally [novartis.com/about], [novartis.com/sites/novartis_com/files/novartis-annual-report-2025.pdf].

Novartis operates across numerous therapeutic areas, continuously exploring science through research and development [novartis.com/].

The company's headquarters are located in Basel, Switzerland [novartis.com/sites/novartis_com/files/novartis-20-f-2024.pdf].

Novartis has a global presence, with divisions and operations spanning across countries in Europe, the Americas, Asia Pacific, and the Middle East & Africa [novartis.com/about/locations]. The company emphasizes building an inspired, curious, and unbossed culture with integrity, recognizing that its people are its greatest strength in driving innovation and bringing bold ideas to life [novartis.com/about/people-and-culture].

Novartis offers a wide range of treatments through its US and International units, though availability varies by country [novartis.com/healthcare-professionals/global-product-portfolio]. Examples of products include Adakveo®, Afinitor®, Aimovig®, and Beovu® [novartis.com/healthcare-professionals/global-product-portfolio]. For eligible patients, Novartis also provides "Managed Access" programs for certain investigational or unapproved treatments [novartis.com/healthcare-professionals/managed-access-programs].

For lower-income countries across Africa, Latin America, and Asia, Novartis has an innovative business model called Novartis Access®. This program provides a portfolio of 15 on- and off-patent medicines for noncommunicable diseases (NCDs) [novartis.com/esg/access/creating-sustainable-business-models/novartis-access]. These medicines are offered as a basket at a price of USD 1 per treatment per month to governments, NGOs, and other institutional customers [novartis.com/sites/novartis_com/files/factsheet-novartis-access.pdf].

In terms of recent pricing changes, Novartis reached an agreement with the US government in December 2025 to take actions aimed at meeting US Administration priorities for drug pricing [novartis.com/us-en/news/media-releases/novartis-and-us-government-reach-agreement-lowering-drug-prices-us]. As part of this agreement, additional Novartis medicines will be made available through direct-to-patient platforms in 2026 [novartis.com/news/media-releases/novartis-and-us-government-reach-agreement-lowering-drug-prices-us]. For patients with prescription drug coverage, Novartis Patient Support can assist with the reimbursement process for certain medications [novartis.com/us-en/patients-and-caregivers/patient-assistance/novartis-patient-support].

Novartis's hiring patterns reflect a strategic emphasis on global expansion and specialized expertise. For instance, the company has job postings for roles like "APP - Chef de Projet Omnicanal" in Paris, France and "扬帆医药代表（MR Intern）" in various Chinese cities, illustrating its commitment to international markets and diverse functional areas. The job openings span various divisions and business units, including Commercial & General Management, Communications & Public Affairs, Data and Digital, and Human Resources, indicating a comprehensive hiring strategy that supports all facets of its operations.

While specific details on recent layoffs are not explicitly available through the provided Novartis homepage content or search results, the consistent and widespread job postings across numerous countries and specialized fields suggest a general trend of growth and strategic talent acquisition. The presence of roles such as a "Postdoc, Manufacturing Science & Technology (MST)" listed on their US career site further reinforces Novartis's dedication to research and development, a critical aspect of its business strategy to discover and develop breakthrough treatments. The company also offers localized career information for specific regions like Novartis Singapore and Novartis Malaysia, demonstrating a tailored approach to talent attraction in different markets.

Novartis places a strong emphasis on candidate experience, as evidenced by its warning against "fake job" scams and its clear statement that Novartis "does not make job offers without interview and never asks candidates for money" on its career search page. This proactive communication helps protect job seekers and maintain the integrity of its hiring process. The broad range of opportunities and the strategic investment in both general recruitment and highly specialized scientific and leadership roles signal Novartis's ongoing commitment to reimagining medicine and improving patient lives globally.

Operating income for FY 2025 stood at USD 17,644 million, marking a significant 21% rise (25% cc), while net income reached USD 13,967 million, an increase of 17% (19% cc). The company also generated a healthy free cash flow of USD 17,596 million in 2025, an 8% increase from 2024. This financial strength enabled continued investment in research and development and strategic acquisitions Novartis annual results | Novartis.

For the first quarter of 2026, Novartis reported net sales of USD 13,113 million. While this represents a slight decrease of 1% (5% cc) from Q1 2025, the company's financial health remains solid.

Operating income for Q1 2026 was USD 4,235 million, with net income at USD 3,156 million.

Free cash flow for the quarter was USD 3,330 million Novartis quarterly financial results | Novartis.

Novartis aims for sustainable performance to benefit patients, employees, shareholders, and society, with solid financial results underpinning its ability to create value Investors | Novartis.

Novartis provides comprehensive financial data, including annual and quarterly results, SEC filings, and information on fixed-income securities, all accessible through its investors section Novartis financial data | Novartis. The company's strong financial performance allows for ongoing investments in R&D and targeted acquisitions, supporting its strategy to reimagine medicine and improve people's lives globally Company overview | Novartis.

The financial stability of Novartis is a cornerstone of its ability to reach nearly 300 million patients worldwide and continue its mission of driving progress in science, medicine, and access to healthcare In 2025, we reached more than 300 million patients worldwide and continued to engage closely with a broad range of stakeholders — a key element in our efforts to collaboratively drive progress in science, medicine and access to healthcare. Financially, we delivered 8% sales growth and 14% core operating income growth in constant currencies (cc), generating USD 17.6 billion in free cash flow 1. This strong performance enabled continued investment in R&D and targeted acquisitions to support sustai.

For investors, Novartis regularly participates in significant financial and healthcare conferences. Notable past and future engagements include the J.P. Morgan Healthcare Conference, Jefferies Healthcare Conference, Bio International Convention, Citi Global Healthcare Conference, UBS European Conference, and ZKB Swiss Equity Conference [prod1.novartis.com/investors/event-calendar, prod1.novartis.com/partnering/partnering-event-calendar, novartis.com/node/662281/printable/pdf]. The company also hosts specific investor events such as "Meet Novartis Management" and an annual ESG investor event.

Novartis is also deeply committed to engaging with healthcare professionals, offering resources and information through medical congresses and country-specific Novartis Pro Portals [novartis.com/healthcare-professionals/medical-congresses-and-events, novartis.com/investors/event-calendar]. Additionally, the company hosts scientific events to foster the open exchange of knowledge and ideas for a broad audience [campus.novartis.com/en/events].

Beyond professional and scientific gatherings, Novartis actively engages with emerging talent through events like the US Early Career Expo. This virtual information session highlights career opportunities and provides insights from current professionals and participants in the One Young World global community, offering a direct look into starting a career at Novartis [novartis.com/events/us-early-career-expo].